Your browser doesn't support javascript.
loading
Graft Versus Host Disease After Intestinal Transplantation: A Single-center Experience.
Kaufman, Stuart S; Hussan, Elsadig; Kroemer, Alexander; Timofeeva, Olga; Pasieka, Helena B; Guerra, Juan Francisco; Yazigi, Nada A; Khan, Khalid M; Ekong, Udeme D; Subramanian, Sukanya; Hawksworth, Jason S; Girlanda, Raffaelle; Ghobrial, Shahira S; Fishbein, Thomas M; Matsumoto, Cal S.
Afiliación
  • Kaufman SS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
  • Hussan E; Georgetown University School of Medicine, Washington, DC.
  • Kroemer A; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
  • Timofeeva O; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
  • Pasieka HB; Georgetown University School of Medicine, Washington, DC.
  • Guerra JF; Georgetown University School of Medicine, Washington, DC.
  • Yazigi NA; Histocompatibility Laboratory, MedStar Georgetown University Hospital, Washington, DC.
  • Khan KM; Georgetown University School of Medicine, Washington, DC.
  • Ekong UD; Department of Dermatology, MedStar Georgetown University Hospital, Washington, DC.
  • Subramanian S; Uniformed Services University of the Health Sciences, Bethesda, MD.
  • Hawksworth JS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
  • Girlanda R; Georgetown University School of Medicine, Washington, DC.
  • Ghobrial SS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
  • Fishbein TM; Georgetown University School of Medicine, Washington, DC.
  • Matsumoto CS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC.
Transplant Direct ; 7(8): e731, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34291153
ABSTRACT

BACKGROUND:

Graft versus host disease (GVHD) is an uncommon but highly morbid complication of intestinal transplantation (ITx). In this study, we reviewed our 17-y experience with GVHD focusing on factors predicting GVHD occurrence and survival.

METHODS:

Retrospective review of 271 patients who received 1 or more ITx since program inception in 2003 with survival analysis using Cox proportional hazard modeling.

RESULTS:

Of 271 patients, 28 developed GHVD 34 (18-66) d after ITx presenting with rash or rash with fever in 26, rectosigmoid disease in 1, and hemolysis in 1; other sites, mainly rectosigmoid colon, were involved in 13. Initial skin biopsy demonstrated classic findings in 6, compatible findings in 14, and no abnormalities in 2. Additional sites of GVHD later emerged in 14. Of the 28 patients, 16 died largely from sepsis, the only independent hazard for death (hazard ratio [HR], 37.4181; P = 0.0008). Significant (P < 0.0500) independent hazards for occurrence of GVHD in adults were pre-ITx functional intestinal failure (IF) (HR, 15.2448) and non-IF diagnosis (HR, 20.9952) and early post-ITx sirolimus therapy (HR, 0.0956); independent hazards in children were non-IF diagnosis (HR, 4.3990), retransplantation (HR, 4.6401), donorrecipient age ratio (HR, 7.3190), and graft colon omission (HR, 0.1886). Variant transplant operation was not an independent GVHD hazard.

CONCLUSIONS:

Initial diagnosis of GVHD after ITx remains largely clinical, supported but not often confirmed by skin biopsy. Although GVHD risk is mainly recipient-driven, changes in donor selection and immunosuppression practice may reduce incidence and improve survival.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transplant Direct Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transplant Direct Año: 2021 Tipo del documento: Article